Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab

REFERENCES

1. 1.↵
   1. Camussi G,
   2. Lupia E

   . The future role of anti tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998;55:613–20.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Miossec P,
   2. van den Berg WB,
   3. Firestein GS

   1. Oppenheimer-Marks N,
   2. Lipsky PE

   . Adhesion molecules in arthritis: control of T cell migration into the synovium. In: Miossec P, van den Berg WB, Firestein GS, editors. T cells in arthritis. Basel, Switzerland: Birkhauser Verlag; 1998:129–48.
3. 3.↵
   1. Gravallese EM,
   2. Goldring SR

   . Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143–51.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Sfikakis PP

   . The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180–210.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Kay J,
   2. Matteson EL,
   3. Dasgupta B,
   4. Nash P,
   5. Durez P,
   6. Hall S,
   7. et al.

   Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964–75. Erratum in: Arthritis Rheum 2010;62:3518.

   OpenUrlCrossRef
6. 6.↵
   1. Keystone E,
   2. Genovese MC,
   3. Klareskog L,
   4. Hsia EC,
   5. Hall S,
   6. Miranda PC,
   7. et al.

   Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129–35. Erratum in: Ann Rheum Dis 2011;70:238–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Keystone EC,
   2. Genovese MC,
   3. Klareskog L,
   4. Hsia EC,
   5. Hall ST,
   6. Miranda PC,
   7. et al.

   Golimumab, a human antibody to TNF-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789–96. Erratum in: Ann Rheum Dis 2011;70:238.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Smolen JS,
   2. Kay J,
   3. Doyle MK,
   4. Landewé R,
   5. Matteson EL,
   6. Wollenhaupt J,
   7. et al.

   Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–21. Erratum in: Lancet 2009;374:1422. Comment in: Lancet 2009;374:178–80.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kavanaugh A,
   2. McInnes I,
   3. Mease P,
   4. Krueger GG,
   5. Gladman D,
   6. Gomez-Reino J,
   7. et al.

   Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Twenty-four week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976–86. Erratum in: Arthritis Rheum 2010;62:2555.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Inman RD,
    2. Davis JC Jr.,
    3. van der Heijde D,
    4. Diekman L,
    5. Sieper J,
    6. Kim SI,
    7. et al.

    Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402–12.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Kremer J,
    2. Ritchlin C,
    3. Mendelsohn A,
    4. Baker D,
    5. Kim L,
    6. Xu Z,
    7. et al.

    Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917–28. Erratum in: Arthritis Rheum 2010;62:3130.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlPubMed
13. 13.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.

    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

    OpenUrlPubMed
14. 14.↵
    1. Prevoo ML,
    2. van’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL

    . Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

    OpenUrlPubMed
15. 15.↵
    1. Wells G,
    2. Becker JC,
    3. Teng J,
    4. Dougados M,
    5. Schiff M,
    6. Smolen J,
    7. et al.

    Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954–60.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. van Riel PL,
    2. van Gestel AM,
    3. Scott DL

    . EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications B.V.; 2000:40.
17. 17.↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR

    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

    OpenUrlPubMed
18. 18.↵
    1. Ware JE Jr.,
    2. Sherbourne CD

    . The MOS 36 item short form health survey (SF 36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

    OpenUrlPubMed